Login / Signup

Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.

Vince B C BiemansJasmijn A M SleutjesAnnemarie C de VriesAlexander G L BodelierGerard DijkstraBas OldenburgMark LöwenbergAdriaan A van BodegravenAndrea E van der Meulen-de JongNanne K H de BoerNidhi SrivastavaRachel L WestTessa E H RömkensCarmen S Horjus Talabur HorjeJeroen M JansenC Janneke van der WoudeJildou HoekstraRinse K WeersmaFiona D M van SchaikFrank HoentjenMarieke J Pieriknull null
Published in: Alimentary pharmacology & therapeutics (2020)
Tofacitinib is an effective treatment for UC after anti-TNF and vedolizumab failure. However, a relatively high rate of adverse events was observed resulting in discontinuation in 6% of patients.
Keyphrases
  • ulcerative colitis
  • rheumatoid arthritis
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • peritoneal dialysis
  • quality improvement
  • patient reported outcomes
  • patients with inflammatory bowel disease